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Summary. Twelve severely depressed patients and 13 
healthy controls were studied under baseline, metyrapone 
and metyrapone plus dexamethasone pretreated condi- 
tions. Lymphocyte proliferation data were obtained by 
concanavalin A, phytohaemagglutinin and pokeweed 
mitogen (PWM) stimulation. There was a decrease in 
PWM-induced B-cell proliferation and an increase in in- 
hibition of spontaneous leucocyte proliferation by dexa- 
methasone added in vitro following metyrapone admin- 
istration in vivo, in healthy controls, which was not pre- 
sent in the depressed patients. These data support he 
concept of a decreased functional plasticity of the gluco- 
corticoid receptor in depression also at the cellular level. 
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Introduction 
Recent interest has focused on the neuroendocrine-im- 
mune interaction in affective disorders. A variety of 
studies have investigated lymphocyte subsets (Schleifer 
et al. 1989), natural killer cell activity (Irwin et al. 1988; 
Schleifer et al. 1989), and the mitogen response to vari- 
ous lectins (Kronfol et al. 1983; Schleifer et al. 1984, 
1985; Cosyns et al. 1989). Although initial studies re- 
ported a decreased mitogen-induced l ucocyte prolifera- 
tion in depressed patients (Kronfol et al. 1983; Schleifer 
et al. 1984), this could not be consistently reproduced in
later investigations (Schleifer et al. 1985). Instead, other 
variables, such as age and severity of depression, seemed 
to play a key role for the lectin-induced blastogenesis 
(Schleifer et al. 1989). 
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Depressed patients exhibit a quite remarkable hyper- 
cotisolaemia during depressive illness (Linkowski et al. 
1985, 1987) and several lines of evidence suggest an im- 
portant link between the hypothalamic-pituitary-adrenal 
axis (HPA) and the immune system (Fauci and Dale 
1974; Cupps and Fauci 1982). Glucocorticoids have been 
shown to inhibit interleukin-1 (IL-1) (Snyder and Unanue 
1982) and IL-2 production with subsequently impaired 
lection-induced blastogenesis (Gillis et al. 1979; Cupps 
and Fauci 1982). Moreover, depletion of glucocorticoids 
by metyrapone (MET) resulted in a decrease in poke- 
weed mitogen (PWM)-induced leucocyte proliferation i
normal volunteers, which was reversed by dexametha- 
sone (DEX) administration (Rupprecht et al., submit- 
ted). 
As human lymphocytes contain glucocorticoid recep- 
tors (GRs) (Lippman and Barr 1977; Schlechte t al. 
1982; Junker 1983), the present study was designed to 
explore the effects of depletion of endogenous glucocor- 
ticoids by MET and subsequent replacement byDEX in 
vivo on lymphocyte proliferation characteristics in vitro 
in depressed patients, when compared with healthy sub- 
jects, as a functional probe for the glucocorticoid recep- 
tor in depression. 
Subjects and Methods 
Subjects 
Three male and nine female subjects with unipolar major 
depressive disorder or bipolar depression aged between 
18 and 66 years (mean + SD, 48.7 + 15.1 years) with a 
mean (+ SD) body weight of 72.5 + 13.4kg and three 
male and ten female healthy controls aged between 33 
and 57 years (mean + SD, 47.6 + 6.2 years) with a mean 
(+ SD) body weight of 69.2 + 8.6kg were studied. All 
subjects were carefully screened for any medical illness 
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Table 1. Demographic data, antidepressants applied prior to the washout period and diagnostic description of the depressed patients 
Patient Age Sex DSM-III-R HRS-D Drug-free Treatment before Depressive 
no. (years) period drug-free period episodes 
(days) 
1 44 F Bipolar disorder, depressed 33 > 28 3 
2 66 F MDD, recurrent, with melancholia 36 > 28 2 
3 61 F MDD, recurrent, with melancholia, 28 > 28 3 
mood congruent psychotic 
4 64 F MDD, recurrent, with melancholia 28 > 28 4 
5 39 F MDD, recurrent 25 7 Amitriptyline 100 mg 3 
6 60 M MDD, recurrent, with melancholia 24 5 Amitriptyline 100 mg 3 
7 60 M MDD, recurrent, with melancholia 28 5 Maprotiline 150 mg 3 
8 34 F MDD, recurrent, with melancholia 28 4 Maprotiline 100 mg 3 
9 54 F Bipolar disorder, depressed 33 > 28 6 
10 18 F MDD, single episode 26 > 28 1 
11 53 M MDD, recurrent 26 > 21 2 
12 34 F MDD, recurrent 39 5 Amitriptyline 150 mg 3 
MDD, Major depressive disorder 
that might influence pituitary-adrenal function by medi- 
cal history, physical examination and routine laboratory 
tests. Four female depressives and four female controls 
were tested during the midluteal phase of the cycle; the 
other females were postmenopausal. 
DSM-III-R (American Psychiatric Association 1987) 
diagnoses were made on all patients by the consensus of 
two psychiatrists, who were blind to laboratory results. 
Severity of depression was assessed by the 21-item Hamil- 
ton Rating Scale for Depression (HRS-D) (Hamilton 
1960). The mean (+ SD) HRS-D score of the patients 
was 29.5 + 4.7, ranging from 24 to 39. Patients were 
studied after a drug-free period of at least 72 h. Details 
of clinical and demographic data of the patients and the 
medication given before the drug-free interval are shown 
in Table 1. 
Controls had no history of psychiatric disorder and 
were medication free for at least 4 weeks. 
Study design 
After the nature of the study had been fully explained, 
written informed consent was obtained from patients 
and controls. The test protocol was approved by the 
ethical committee of the University of Wfirzburg and the 
requirements of the revised version of the Helsinki Dec- 
laration were strictly adhered to. All subjects were ad- 
mitted to a sleep laboratory unit at least lh  prior to drug 
administration or blood sampling. 
For determination of lymphocyte proliferation para- 
meters, glucocorticoid binding characteristics, and hor- 
mone data, 50 ml blood was collected at 4 p.m. into pre- 
chilled plastic tubes containing ethylenediaminetetraace- 
tic acid (EDTA) on 3 consecutive days. On day 1 base- 
line values were obtained. On day 2 the subjects were 
pretreated with 1.5 g MET at 9 a.m., administered orally 
with milk to avoid severe gastric symptoms. A dose of 
lmg DEX was given orally at l lp .m.  On day 3 adminis- 
tration of 1.5 g MET was performed as described for the 
day before. Of the subjects 80% experienced a transient 
dizziness and a hot flush after MET administration, 
which disappeared spontaneously within 45-60 rain. 
Assays 
Chemicals. [3H]Thymidine (specific activity 25 Ci/mmol) 
was obtained from Amersham (Buckinghamshire, UK). 
Phosphate-buffered saline (PBS) was obtained from Boeh- 
ringer (Mannheim, FRG).  Concanavalin A (Con A), 
phytohemagglutinin A (PHA), PWM and sodium metri- 
zoate-Ficoll were obtained from Sigma (St. Louis, Mo.), 
and Rotiszint 22 was obtained from Roth (Karlsruhe, 
FRG). The culture medium consisted of RPMI medium 
(Boehringer, Mannheim, FRG) containing 2mM L-glu- 
tamate (Biochrom, Berlin, FRG) and 0.1mg/ml genta- 
micin (Biochrom) with 8% fetal calf serum (Biochrom) 
added. 
Preparation of cells. A mononuclear cell fraction was 
prepared under sterile conditions by sodium metrizoate- 
Ficoll density gradient centrifugation (Boyum 1968). 
Cells were washed two times in PBS for 10 rain and incu- 
bated for 60 min at 37~ to allow sufficient dissociation 
of endogenous hormone followed by a third washing 
procedure. The final concentration of cells was deter- 
mined using a Coulter Counter (Model $5, Coulter Elec- 
tronics, UK). Viability of cells exceeded 95%, as judged 
from their ability to exclude trypan blue. Contamination 
by erythrocytes was less than 10%; contamination by 
granulocytes and monocytes was less than 8% and did 
not differ between the 3 test days and between patients 
and controls. 
Lymphocyte proliferation tests. Lymphocyte prolifera- 
tion experiments were carried out in plastic microtiter 
plates in a total volume of 0.22 mL. A quantity of 25,000 
cells was incubated in culture medium for 60 h to evalu- 
ate Con A- and PHA-generated T-cell mitogenesis and 
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for 120h to evaluate PWM-generated B-cell prolifera- 
tion and glucocorticoid-induced inhibition of spontane- 
ous mitogenesis in a sterile incubator at 37~ in a humid- 
ified atmosphere with 5% CO2. Concentrations of 0.5, 1, 
5, 10, 20, 40, and 50 gg/ml were used to evaluate the 
dose/response curves of Con A- and PWM-induced ef- 
fects, and concentrations of 0.1, 0.5, 1, 2.5, 5, 10, and 
20 gg/ml for determination f the effects of PHA on lym- 
phocyte proliferation. In vitro glucocorticoid effects 
were assessed by increasing concentrations ranging from 
10 -l~ to 10-7M DEX on baseline lymphocyte prolifera- 
tion. A quantity of 0.5 pCi [3H]thymidine was added 5 h 
prior to termination of the incubation period. Incorpo- 
rated [3H]thymidine was separated from free nucleotide 
by rapid filtration through Whatman GF/B filters with a 
Titertek cell harvester by an ll-s wash with distilled 
water at room temperature. The filters were transferred 
into plastic vials, 5ml of a toluene-based scintillation 
cocktail was added (Rotiszint 22) and they were moni- 
tored for tritium in a Beckman LS 5000TD counter at 
about 54% efficiency. All samples were assayed in tripli- 
cate with a variation within a single experiment of less 
than 15%. 
Glucocorticoid receptor assay. Binding characteristics of 
the glucocorticoid receptor (GR) (receptor sites per cell 
and Kd) were determined using saturation experiments 
by [3H]dexamethasone as described previously (Rup- 
precht et al. 1990). One part of the mononuclear cell 
fraction comprising T- and B-lymphocytes was assayed 
for GR content immediately after preparation, and the 
other was used for proliferation experiments in culture. 
Hormone assays. The adreno-corticotrophic ormone 
(ACTH) was measured by an immunoradiometric assay 
(IRMA) supplied by the Nichols Institute (San Juan 
Capistrano, Calif.), which does not require extraction 
procedures (Raft and Findling 1989). A soluble sand- 
wich complex is formed by a 125I-labelled monoclonal 
antibody directed against N-terminal ACTH and a biotin- 
coupled polyclonal antibody against C-terminal ACTH. 
The sandwich complexes are bound by adding avidin- 
coated plastic beads. Unbound components are washed 
away and the radioactivity bound to the solid phase is 
monitored in a gamma counter. The lower detection limit 
was 1.5 pmol/1, and the intra- and interassay coefficients 
of variation were 3% and 6.8%, respectively. Values 
below the detection limit were recorded as 1.5 pmol/1. 
Cortisol was measured by a direct radio-immunoas- 
say (RIA) (Stalla et al. 1981). The lower detection limit 
was 25 nmol/1, and the intra- and interassay coefficients 
of variation were 5% and 9%, respectively. As there was 
a cross-reactivity of our cortisol antibody with 11-deoxy- 
cortisol of about 15%, determinations of cortisol values 
following MET administration would not be accurate 
and were excluded from further analysis. 
Data analysis 
Lymphocyte proliferation was expressed in terms of a 
stimulation i dex defined by the ratio thymidine uptake 
(DPM) of stimulated/unstimulated leucocytes. The area 
under the dose/response curves (AUC) (stimulation i dex 
* lectin concentrations) was determined using trapezoi- 
dal integration. 
The results are expressed as the mean + SD, and as 
the mean + SE in the figures. Data were analysed using 
the t-test for paired samples and analysis of variance 
(ANOVA) for repeated measurements forcomparisons 
within groups, and ANOVA followed by post hoc com- 
parison with Student's t-test for comparisons between 
groups. Correlation data were obtained by Pearson's 
product-moment correlation. All significance l vels are 
two-tailed. 
Results 
Administration of MET provoked a marked increase in 
ACTH in patients and controls, which was avoided by 
DEX pretreatment (Table 2). ACTH values did not dif- 
fer between patients and controls following MET admin- 
istration, indicating an equal amount of 11-[3 hydroxy- 
lase inhibition in both groups. There was a significant in- 
crease in GR sites per cells following MET administration 
in healthy controls, which was not present in depressives 
(Table 3). 
DPM of the unstimulated thymidine uptake of pa- 
tients and controls are given in Table 4. Depletion of en- 
dogenous cortisol by MET and subsequent replacement 
by DEX did not alter Con A- and PHA-induced mito- 
genesis in patients and controls (Table 5), and there was 
no significant difference between the two groups on ei- 
Table 2. Mean + SD adrenocorticotrophic hormone (ACTH) lev- 
els (pmol/1) of patients during depression ( = 12) and of healthy 
controls (n = 13) under baseline, metyrapone (MET), and MET + 
dexamethasone (DEX) pretreated conditions, and baseline cor- 
tisol values (nmol/1) 
ACTH Patients Controls 
Mean SD Mean SD 
Baseline 4.2 1.5 3.5 0.8 
MET 24.9 19.4 26.4 19.5 
MET + DEX 4.0 0.2 1.5 0.1 
Cortisol 273.1 104.8 225.7 77.3 
Table 3. Mean _+ SD glucocorticoid receptor (GR) sites per cell of 
patients during depression ( = 12) and controls (n = 13) under 
baseline, MET and MET + DEX pretreated conditions 
Patients Controls 
Mean SD Mean SD 
Baseline 3 219 1173 3 290 787 
MET 3110 1114 5495* 2488 
MET + DEX 2735 1080 3863 2117 
Analysis of variance (ANOVA) for repeated measurements (* P < 
0.01) 
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Table 4. Mean + SD DPM of unstimulated leucocytes ( timulation 
index = 1) for the dose/response curves for concanavalin A (Con A) 
and pbytohaemagglutinin (PHA) after 60 h culture and for poke- 
weed mitogen (PWM) and spontaneous lymphocyte proliferation 
9 after 120 h culture 
Con A PHA PWM 
Patients 
Baseline 1012 + 440 1077 _+ 464 2 54i + 1208 
MET a 908 +_ 571 992 _+ 528 2753 + 2465 
MET + DEX b 932 + 735 1026 _+ 675 2181 + 2054 
Controls 
Baseline 828 + 528 1023 _+ 767 2928 _+ 1408 
MET 835 + 396 919 • 318 3573 + 2661 
MET + DEX 851 + 373 845 _+ 302 2236 + 2178 
a Metyrapone 
b Dexamethasone 
The DPM are given for the depressed patients and the normal con- 
trols 
Table 5. Mean + SD areas under the stimulation curves for Con A 
(AUCco~ A)) and for PHA (AUCp~A) induced leucocyte prolifera- 
tion of patients during depression (n = 12) and of healthy controls 
(n = 13) under baseline, MET, and MET + DEX pretreated con- 
ditions 
Patients Controls 
Mean SD Mean SD 
Con A 
Baseline 208.2 116.7 267.8 178.1 
MET 269.6 203.5 232.2 157.7 
MET + DEX 361.0 330.0 272.0 188.6 
PHA 
Baseline 413.9 266.3 456.3 266.6 
MET 362.2 197.4 348.1 204.8 
MET + DEX 381.7 204.2 389.9 214.4 
ther test day. While PWM-generated B-cell mitogenesis 
(AUCpwM) was significantly lower following MET ad- 
ministration when compared to baseline or MET + DEX 
pretreated conditions in controls (Fig. 1) (F= 6.3, P< 
0.03; F=5.3 ,  P<0.05) ,  a comparable ffect was not 
present in depressives (Fig. 2) (F :  1.7, P < 0.2; F = 1.9, 
P < 0.2). 
DEX added in vitro suppressed spontaneous lympho- 
cyte proliferation in a dose-dependent manner in pa- 
tients and controls (Figs. 3, 4). This effect (AUCD~x) 
was more marked after 11-[3 hydroxylase inhibition by 
MET when compared with baseline or MET + DEX 
pretreated conditions in controls (Fig. 3) (F= 6.5, P < 
0.03; F = 12.9, P < 0.006), but not in depressives (Fig. 4) 
(F= 0.7, P< 0.4; F= 3.4; P< 0.1). 
There were no significant associations between age, 
sex, number of depressive pisodes, length of the washout 
period, treatment prior to the washout period, ACTH,  
cortisol and GR concentrations and any leucocyte prolif- 
eration parameters. 
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Fig. 1. Mean dose/response curves for pokeweed mitogen (PWM)- 
generated lymphocyte proliferation at 1600 h on 3 consecutive days 
under baseline (o), metyrapone (MET) (+) and metyrapone plus 
dexamethasone (MET+ DEX) (*) pretreated conditions in heal- 
thy controls (n = 13). SEs are omitted for clarity of presentation. 
The inset shows the mean + SE areas under the curves (AUC) of 
the three dose/response curves. The asterisk indicates asignificant 
difference between MET pretreated values when compared with 
baseline or MET + DEX pretreated values 
Discussion 
We could detect neither a significant difference with re- 
gard to Con A-, PHA-,  or PWM-induced leucocyte pro- 
liferation nor in inhibition of spontaneous leucocyte pro- 
liferation by in vitro added DEX between depressed pa- 
tients and normal controls. The higher DPM following 
PWM stimulation in depressed patients did not reach 
even trend level. Our results differ from several observa- 
tions reporting a clear-cut attenuated mitogen response 
following administration of various lectins in depressed 
patients (Kronfol et al. 1983; Schleifer et al. 1984; Co- 
syns et al. 1989). However, the mitogen-induced blasto- 
genesis has recently been attributed more to factors such 
as age, severity of depression, and hospitalization effects 
than to the diagnosis itself (Schleifer et al. 1989). It seems 
likely that the conclusion that there is an impaired lym- 
phocyte function in depression has been premature. We 
could not dichotomize into subjects with adequate and 
inadequate DEX suppression test results as done by 
Lowy et al. (1988), as our subjects were depleted of en- 
dogenous cortisol by MET. 
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Fig. 2. Mean dose/response curves for PWM-generated lympho- 
cyte proliferation at 1600 h on 3 consecutive days under baseline 
(o), metyrapone (MET) (+) and metyrapone plus dexamethasone 
(MET + DEX) (*) pretreatcd conditions in depressed patients (n = 
12). SEs are odmitted for clarity of presentation. The inset shows 
the mean + SE areas under the curves (AUC) of the three dose/re- 
sponse curves 
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Fig. 4. Mean dose/response curves for dexamethasone (DEX) in- 
duced inhibition of spontaneous lymphocyte proliferation at 4 p.m. 
on 3 consecutive days under baseline (o), metyrapone (MET) (+) 
and metyrapone plus dexamethasone (MET + DEX) (*) pretreated 
conditions in depressed patients (n = 12). SEs are omitted for clar- 
ity of presentation. The inset shows the mean + SE areas under the 
curves (AUC) of the three dose/response curves 
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Fig. 3. Mean dose/response curves for dexamethasone (DEX)-in- 
duced inhibition of spontaneous lymphocyte proliferation at 4 p.m. 
on 3 consecutive days under baseline (o), metyrapone (MET) (+) 
and metyrapone plus dexamethasone (MET + DEX) (*) pretreated 
conditions in healthy controls (n = 13). SEs are omitted for clarity 
of presentation. The inset shows the mean + SE areas under the 
curves (AUC) of the three dose/response curves. The asterik indi- 
cates a significant difference betwen MET pretreated values when 
compared with baseline or MET + DEX pretreated values 
There was a decrease in PWM-induced B-cell prolif- 
eration following MET administration i  healthy con- 
trols which was reversed by DEX administration. As 
cortisol is an important co-factor for the expression of 
IL-1 receptors (Akahoshi et al. 1988) and IL-1 plays a 
major role in the proliferation of B-cells and antibody 
production, the impaired lymphocyte response to PWM 
following MET administration might reflect the lack of 
endogenous glucocorticoids. However, such an effect on 
MET was not present in the depressed patients. More- 
over, depressed patients did not exhibit the enhanced ef- 
fect of in vitro administered DEX following MET ad- 
ministration as observed in normal controls (Rupprecht 
et al., submitted). Differences in the rate of 11-13 hy- 
droxylase inhibition by MET between patients and con- 
trols cannot account for these results, as ACTH and l l -  
deoxycortisol levels (Rupprecht et al. 1991) are not dif- 
ferent between groups following MET administration. 
Our observations support he hypothesis of a decreased 
functional plasticity of the glucocorticoid receptor at the 
cellular level. Previous investigations showed both an at- 
tenuated action of glucocorticoid hormones on various 
endocrine systems in depressed patients (Rupprecht et 
al. 1987, 1988, 1989) and a diminished autoregulatory 
potency of the glucocorticoid receptor on leucocytes it- 
self (Rupprecht et al. 1991). In summary, several lines of 
evidence point to an attenuated action of glucocorticoids 
at the humoral and cellular level, which might be impor- 
tant for a potential disturbance of the immune-endocrine 
connection in depression. Since IL-1 immunoreactive 
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f ibres have recent ly been ident i f ied in the paraventr icu-  
lar nucleus of the human hypotha lamus (Breder  et al. 
1988), and IL-1 is capable of increasing ACTH levels 
and proop iomelanocor t in  mRNA in the AtT-20 cell (Fu- 
kata  et al. 1989), it may be concluded that there is a close 
funct ional  and neuro-anatomica l  l ink between the hypo- 
tha lamic-p i tu i tary-adrenal  axis and the immune system 
which possib ly is affected during depressive disorder.  
References 
Akahoshi T, Oppenheim JJ, Matsushima K (1988) Induction of 
high-affinity interleukin-1 receptor on human peripheral blood 
lymphocytes by glucocorticoid hormones. J Exp Med 167: 
924-936 
American Psychiatric Association (1987) Committee on Nomen- 
clature and Statistics. Diagnostic and statistical manual of 
mental disorders 3rd edn, revised. American Psychiatric As- 
sociation, Washington DC 
Boyum A (1968) Separation of leukocytes from blood and bone 
marrow. Scand J Clin Lab Invest 21:97-107 
Breder CD, Dinarello CA, Saper CB (1988) Interleukin-1 immu- 
noreactive innervation of the huma hypothalamus. Science 
240 : 321-324 
Cosyns P, Maes M, Vandewoude M, Stevens WJ, De Clerck LS, 
Schotte C (1989) Impaired mitogen-induced lymphocyte re- 
sponses and the hypothalamic-pituitary-adrenal axis in depres- 
sive disorders. J Affect Disord 16 : 41-48 
Cupps TR, Fauci AS (1982) Corticosteroid-mediated immunoreg- 
ulation in man. Immunol Rev 65 : 133-155 
Fauci AS, Dale DC (1974) The effect of in vivo hydrocortisone on
subpopulations of human lymphocytes. J Clin Invest 53 : 240- 
246 
Fukata J, Usui T, Naitoh Y, Nakai Y, Imura H (1989) Effects of 
recombinant human interleukin-lc~, 1 [3, 2 and 6 on ACTH syn- 
thesis and release in the mouse pituitary tumor cell line AtT- 
20. J Endocrinol 122 : 33-39 
Gillis S, Crabtree GR, Smith KA (1979) Glucocorticoid-induced 
inhibition of T-cell growth factor production. I The effect on 
mitogen-induced lymphocyte proliferation. J Immunol 123: 
1624-1631 
Hamilton M (1960) A rating scale for depression. J Neurol Neuro- 
surg Psychiatry 23 : 56-62 
Irwin M, Daniels M, Rish SC, Bloom E, Weiner H (1988) Plasma 
cortisol and natural killer cell activity during bereavement. 
Biol Psychiatry 24:173-178 
Junker K (1983) Glucocorticoid receptors of human mononuclear 
leukocytes in vitro. J Clin Endocrinol Metab 57 : 506-512 
Kronfol Z, Silva J, Greden J, Dembinski S, Gardner R, Carroll B 
(1983) Impaired lymphocyte function in depressive illness. Life 
Sci 33 : 241-247 
Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, 
Golstein J, Copinschi G, Cauter E van (1985) The 24-hour 
profile of adrenocorficotropin and cortisol in major depressive 
illness. J Clin Endocrinol Metab 61 : 429-438 
Linkowski P, Medlewicz J, Kerkhofs M, Leclercq R, Goldstein J,
Brasseur M, Copinschi G, Cauter E van (1987) 24-hour pro- 
files of adrenocorticotropin, cortisol, and growth hormone in 
major depressive illness: effect of antidepressant treatment. J 
Clin Endocrinol Metab 65:141-152 
Lippman M, Barr R (1977) Glucocorticoid receptors in purified 
subpopulations of human peripheral blood lymphocytes. J 
Immunol 118:197%1981 
Lowy MT, Reder AT, Gormley GJ, Meltzer HY (1988) Compari- 
son of in vivo and in vitro glucocorticoid sensitivity in depres- 
sion: relationship to the dexamethasone suppression test. Biol 
Psychiatry 24 : 619-630 
Raft H, Findling JW (1989) A new immunoradiometric assay for 
corticotropin evaluated in normal subjects and in patients with 
Cushing's yndrome. Clin Chem 35 : 596-600 
Rupprecht R, Barocka A, Jecht E, Noder M, Pichl J, Schwarz W 
(1987) Prolactin response to dexamethasone: a study on nor- 
mal contral and depressed patients. Acta Psychiatry Scand 
76:139-143 
Rupprecht R, Barocka A, Beck G, Schrell U, Pichl J (1988) Pre- 
and postdexamethasone plasma ACTH and ]3-endorphin levels 
in endogenous and non-endogenous depression. Biol Psychia- 
try 23 : 531-535 
Rupprecht R, Rupprecht C, Rupprecht M, Noder M, Mahlstedt J 
(1989) Triiodothyronine, thyroxine and TSH response to dexa- 
methasone in depressed patients and normal controls. Biol 
Psychiatry 25 : 22-32 
Rupprecht R, Kornhuber J, Wodarz N, G6bel C, Lugauer J, Sinz- 
ger C, Riederer P, Mfiller OA (1990) Characterization f glu- 
cocorticoid binding capacity in human mononuclear leuko- 
cytes: increase by metyrapone is prevented by dexamethasone 
pretreatment. J Neuroendocrinol 2: 803-806 
Rupprecht R, Kornhuber J, Wodarz N, Lugauer J, G6bel C, 
Haack D, Mtiller OA, Beck G, Riederer P, Beckmann H 
(1991) Disturbed glucocorticoid receptor autoregulation a d 
corticotropin response to dexamethasone i  depressives pre- 
treated with metyrapone. Biol Psychiatry (in press) 
Schlechte JA, Ginsberg BH, Sherman BM (1982) Regulation of 
the glucocorticoid receptor in human lymphocytes. J Steroid 
Biochem 16 : 69-74 
Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, 
Stein M (1984) Lymphocyte function in major depressive dis- 
order. Arch Gen Psychiatry 41 : 484-486 
Schleifer SJ, Keller SE, Siris SG, Davis KL, Stein M (1985) De- 
pression and immunity: lymphocyte function in ambulatory de- 
pressed patients, hospitalized schizophrenic patients, and pa- 
tients hospitalized for herniography. Arch Gen Psychiatry 42 : 
129-133 
Schleifer SJ, Keller SE, Bond RN, Cohen J, Stein M (1989) Major 
depression and immunity: role of age, sex, severity, and hos- 
pitalization. Arch Gen Psychiatry 46 : 81-87 
Snyder DS, Unanue ER (1982) Corticosteroids inhibit murine 
macrophage Ia expression and interleukin-1 production. J 
Immunol 129 : 1803-1805 
Stalla GK, Giesemann G, Mfiller OA, Wood WG, Scriba PC 
(1981) The development of a direct homologous radioimmu- 
noassay for serum eortisol. J Clin Chem Clin Biochem 
